ERC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Endocrine-Related Cancer 10 (4) 451-458    DOI: 10.1677/erc.0.0100451
Copyright © 2003 by the Society for Endocrinology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (24)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de Herder, W.
Right arrow Articles by Lamberts, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Herder, W.
Right arrow Articles by Lamberts, S.
Endocrine Related Cancer, Vol 10, Issue 4, 451-458
Copyright © 2003 by Society for Endocrinology

Articles

Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours

WW de Herder, LJ Hofland, AJ van der Lely, and SW Lamberts


Five somatostatin receptor (sst) subtype genes, sst(1), sst(2), sst(3), sst(4) and sst(5), have been cloned and characterised. The five sst subtypes all bind natural somatostatin-14 and somatostatin-28 with high affinity. Endocrine pancreatic and endocrine digestive tract tumours also express multiple sst subtypes, but sst(2) predominance is generally found. However, there is considerable variation in sst subtype expression between the different tumour types and among tumours of the same type. The predominant expression of sst(2) receptors on pancreatic endocrine or carcinoid tumours is essential for the control of hormonal hypersecretion by the octapeptide somatostatin analogues such as octreotide and lanreotide. Somatostatin and its octapeptide analogues are also able to inhibit proliferation of normal and tumour cells. The high density of sst(2) or sst(5) on pancreatic endocrine or carcinoid tumours further allows the use of radiolabelled somatostatin analogues for in vivo visualisation. The predominant expression of sst(2) receptors in these tumours and the efficiency of sst(2) receptors to undergo agonist-induced internalisation is also essential for the application of radiolabelled octapeptide somatostatin analogues. Currently, [(111)In-DTPA(0)]octreotide, [(90)Y-DOTA(0),Tyr(3)]octreotide, [(177)Lu-DOTA(0)Tyr(3)]octreotate, [(111)In-DOTA(0)]lanreotide and [(90)Y-DOTA(0)]lanreotide can be used for this purpose.


This article has been cited by other articles:


Home page
 Mol. Endocrinol.Home page
M. Grant, H. Alturaihi, P. Jaquet, B. Collier, and U. Kumar
Cell Growth Inhibition and Functioning of Human Somatostatin Receptor Type 2 Are Modulated by Receptor Heterodimerization
Mol. Endocrinol., October 1, 2008; 22(10): 2278 - 2292.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
S. Grozinsky-Glasberg, I. Shimon, M. Korbonits, and A. B Grossman
Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms
Endocr. Relat. Cancer, September 1, 2008; 15(3): 701 - 720.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. Torrisani, N. Hanoun, H. Laurell, F. Lopez, J.-J. Maoret, A. Souque, C. Susini, P. Cordelier, and L. Buscail
Identification of an Upstream Promoter of the Human Somatostatin Receptor, hSSTR2, Which Is Controlled by Epigenetic Modifications
Endocrinology, June 1, 2008; 149(6): 3137 - 3147.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. P. Koopmans, O. C. Neels, I. P. Kema, P. H. Elsinga, W. J. Sluiter, K. Vanghillewe, A. H. Brouwers, P. L. Jager, and E. G.E. de Vries
Improved Staging of Patients With Carcinoid and Islet Cell Tumors With 18F-Dihydroxy-Phenyl-Alanine and 11C-5-Hydroxy-Tryptophan Positron Emission Tomography
J. Clin. Oncol., March 20, 2008; 26(9): 1489 - 1495.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Ceppi, M. Volante, A. Ferrero, L. Righi, I. Rapa, R. Rosas, A. Berruti, L. Dogliotti, G. V. Scagliotti, and M. Papotti
Thymidylate Synthase Expression in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors
Clin. Cancer Res., February 15, 2008; 14(4): 1059 - 1064.
[Abstract] [Full Text] [PDF]

Home page
 Home page
C. M. Intenzo, S. Jabbour, H. C. Lin, J. L. Miller, S. M. Kim, D. M. Capuzzi, and E. P. Mitchell
Scintigraphic Imaging of Body Neuroendocrine Tumors
RadioGraphics, September 1, 2007; 27(5): 1355 - 1369.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
S. Arena, A. Pattarozzi, A. Massa, J.-P. Esteve, R. Iuliano, A. Fusco, C. Susini, and T. Florio
An Intracellular Multi-Effector Complex Mediates Somatostatin Receptor 1 Activation of Phospho-Tyrosine Phosphatase {eta}
Mol. Endocrinol., January 1, 2007; 21(1): 229 - 246.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
S. V. de Sa, M. L. Correa-Giannella, M. C. Machado, J. J. S de Souza, M. A. A. Pereira, R. A. Patzina, S. A. C. Siqueira, M. C. C. Machado, and D. Giannella-Neto
Somatostatin receptor subtype 5 (SSTR5) mRNA expression is related to histopathological features of cell proliferation in insulinomas.
Endocr. Relat. Cancer, March 1, 2006; 13(1): 69 - 78.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
G A Kaltsas, D Papadogias, P Makras, and A B Grossman
Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues
Endocr. Relat. Cancer, December 1, 2005; 12(4): 683 - 699.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the Society for Endocrinology.